New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:01 EDTGNCA, SHPGGenocea names Jonathan Poole as CFO
Genocea Biosciences (GNCA) announced the appointment of Jonathan Poole to the position of CFO. Poole joins Genocea from Shire plc (SHPG).
News For GNCA;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
12:51 EDTSHPGIntercept said to explore sale after suitors reportedly come calling
Shares of Intercept Pharmaceuticals (ICPT), which has often been rumored in the past to be a potential takeover target, are surging in afternoon trading after Reuters reported that the company is exploring a potential sale. WHAT'S NEW: Reuters, citing people familiar with the matter, said the company, which focuses on treatments for liver disease, has been working with investment banker advisors to explore a sale after receiving interest from other companies. PRIOR CHATTER: Earlier this week, United Kingdom blog Proactive Investors discussed "reheated rumors" of a takeover of Intercept, which claimed the company was teaming up with CenterView Partners to advise on a sale. It mentioned AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). On February 2, the U.K.'s Daily Mail said rumors that several big-name pharmaceutical companies were interested in Intercept had been "doing the rounds again," noting that trader chatter pointed to purported interest from Shire, Gilead (GILD), Bristol-Myers (BMY) and Pfizer (PFE). WHAT'S NOTABLE: Yesterday, the FDA issued a notice to announce a forthcoming meeting of the Gastrointestinal Drugs Advisory Committee to discuss the new drug application for obeticholic acid oral tablets submitted by Intercept Pharmaceuticals, proposed for the treatment of primary biliary cirrhosis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. PRICE ACTION: In afternoon trading, Intercept jumped 35% to $127.85 per share. Reference Link
11:31 EDTSHPGShire price target lowered to $230 from $288 at Northland
Subscribe for More Information
February 11, 2016
09:21 EDTSHPGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Expedia (EXPE), up 8.4%... Tripadvisor (TRIP), up 10.8%... Cisco (CSCO), up 6%... LendingClub (LC), up 8.8%... Tesla (TSLA), up 3.5%... Shire (SHPG), up 3.1%. ALSO HIGHER: 3D Systems (DDD), up 13.4% after reporting preliminary Q4 revenue. DOWN AFTER EARNINGS: Flowers Foods (FLO), down 17.7%... Incyte (INCY), down 14.3%... LivePerson (LPSN), down 16.7%... Twitter (TWTR), down 5.5%... Mylan (MYL), down 12.5%... PepsiCo (PEP), down marginally. ALSO LOWER: Visa (V), down 3% after being downgraded to Neutral from Buy at BofA/Merrill... Mastercard (MA), down 3% after being downgraded to Neutral from Buy at BofA/Merrill.
09:06 EDTSHPGShire sees FY16 non-GAAP EPS growth of 7%-10%, consensus $12.79
Subscribe for More Information
09:06 EDTSHPGShire reports 14 programs either in Phase 3 or Phase 3 ready entering 2016
09:05 EDTSHPGShire reports FY15 non-GAAP EPS $11.68, consensus $11.57
Reports FY15 revenue $6.42B, consensus $6.40B. Reports FY15 Product sales $6.1B. Reports FY15 Product sales excluding INTUNIV $6.04B.
07:37 EDTGNCAGenocea reports Q4 EPS (37c), consensus (40c)
Subscribe for More Information
February 10, 2016
17:28 EDTSHPGShire partner Shionogi submits NDA in Japan for ADHD treatment for children
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aralez (ARLZ) initiated with a Buy at Guggenheim... Atlassian (TEAM) initiated with a Neutral at Baird... CareDx (CDNA) initiated with a Buy at Janney Capital... Denison Mines (DNN) initiated with a Buy at Roth Capital... Deutsche Boerse (DBOEY) initiated with a Neutral at Exane BNP Paribas... Instructure (INST) initiated with an Outperform at Oppenheimer... Kirkland's (KIRK) initiated with a Buy at B. Riley... Mesa Labs (MLAB) initiated with a Buy at Janney Capital... Natural Grocers (NGVC) initiated with a Hold at Deutsche Bank... Nordex (NRDXF) initiated with an Overweight at Barclays... Old Line Bancshares (OLBK) initiated with a Market Perform at Keefe Bruyette... Shire (SHPG) initiated with a Neutral at Guggenheim... T2 Biosystems (TTOO) initiated with a Buy at Cantor... iRobot (IRBT) initiated with a Buy at Chardan.
09:19 EDTSHPGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Akamai (AKAM), up 16.5%... Prospect Capital (PSEC), up 10.7%... Panera Bread (PNRA), up 2%. ALSO HIGHER: Deutsche Bank (DB), up 6.1% after the Financial Times reported that the company is considering a multibillion bond buyback... Fitbit (FIT), up 3.7% after Marc Benioff reported a 5% stake in the company... FireEye (FEYE), up 3.9% after being upgraded to Buy from Neutral at BTIG... Shire (SHPG), up 1.7% after being upgraded to Outperform from Sector Perform at RBC Capital. DOWN AFTER EARNINGS: Time Warner (TWX), down 7.6%... Disney (DIS), down 5.1%... SolarCity (SCTY), down 27.8%. ALSO LOWER: CTI BioPharma (CTIC), down 38% after the FDA placed pacritinib IND on full clinical hold... Mast Therapeutics (MSTX), down 40.1% after 29.1M share Spot Unit offering priced at $0.275.
08:25 EDTSHPGShire upgraded on valuation at RBC Capital
As noted earlier, RBC Capital upgraded Shire to Outperform from Sector Perform. The firm believes that the recent decline in the stock more than accounts for any competitive risks facing the company's Baxalta drug. Target $240.
07:19 EDTSHPGShire says David Kappler to step down as deputy chairman
Subscribe for More Information
06:28 EDTSHPGShire upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
February 9, 2016
16:14 EDTSHPGShire initiated with a Neutral at Guggenheim
09:56 EDTSHPGIntercept higher following report of vague takeover chatter
Shares of Intercept Pharmaceuticals (ICPT) are moving after United Kingdom blog Proactive Investors discussed "reheated rumours" of a takeover. "Vague talk" has Intercept teaming up with CenterView Partners to advise on a sale, the blog states. It mentions AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). Shares of Intercept, which is developing treatments for chronic liver diseases, are up 4% to $97.39 in early trading.
February 4, 2016
16:00 EDTSHPGShire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.
February 3, 2016
08:07 EDTSHPGMedgenics names Brian Piper to succeed John Leaman as CFO
Subscribe for More Information
February 2, 2016
09:46 EDTSHPGIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use